Opendata, web and dolomites

Metachip SIGNED

A pan-cancer diagnostic platform based on nanobiotechnology and machine learning for simple and accessible early cancer detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Metachip" data sheet

The following table provides information about the project.

Coordinator
CQX LAB UK LTD 

Organization address
address: UNIT 6 QUEENS YARD, WHITE POST LANE
city: LONDON
postcode: E9 5EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://conquerxlab.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CQX LAB UK LTD UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Cancer is the second highest cause of death in the EU, with more than 1.3 million deaths attributable to cancer each year. Early detection of cancer is crucial to increasing the chances of survival for patients. For example, the average cancer survival rate is 83% when caught early and only 17% when diagnosed at an advanced stage. This is compounded by the difficulty and expense of screening for early stage cancers. Beyond expensive and specialist whole body imaging techniques such as MRI, there is still no commercially available general test for detecting any type of cancer before symptoms present themselves. Staggeringly, 52% of cancer deaths are due to a lack of preventative tests. Metachip, from ConquerX, is a revolutionary pan-cancer diagnostic platform that enables early-stage detection of the 10 most common types of cancer from a single, simple blood test. The platform consists of a reading device, disposable chips coated with a proprietary nanocomposite, and a diagnostic software suite powered by cutting edge artificial intelligence. The Metachip test is cost effective, fast (one hour to results), and does not require specialist analytical techniques or lab facilities. By delivering the Metachip platform, ConquerX aim to make early-stage detection of cancer available to every hospital in the EU and worldwide. During the phase 1 feasibility study, ConquerX will establish a sound go-to-market strategy and supply chain, and will draft further development plans. During the second phase of the innovation project, ConquerX will optimise the diagnostic platform, scale-up manufacturing, perform clinical validation activities with partner hospitals and gain regulatory approval.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "METACHIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "METACHIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More